Ajanta Pharma Limited (NSE: AJANTPHARM, BSE: 532331) is a Mumbai, Maharashtra-based company in the Pharmaceuticals industry. With a market capitalisation of ₹41,474 Cr, it ranks #232 by market cap among the 6,197 Indian listed companies on FinBizNet, and #3 of 63 in Pharmaceuticals. At ₹3,279.00 (as of 16 Nov 2026), the share price is 13.6% below its 52-week high of ₹3,796.00 and 34.1% above its 52-week low of ₹2,445.80. The share price is up 27.8% over one year and down 9.1% over three months.
| Current Price | ₹3,279.00 |
|---|---|
| Market Cap | ₹41,474 Cr |
| NSE Symbol | AJANTPHARM |
| BSE Code | 532331 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 39.4 |
| Return on Equity | 25.39% |
| Return on Assets | 14.85% |
| 52-Week Range | ₹2,445.80 – ₹3,796.00 |
| 1-Year Price Change | +27.8% |
| 3-Month Price Change | -9.1% |
| Beta (1Y) | 0.19 |
| Dividend Yield | 1.92% |
| Headquarters | Mumbai, Maharashtra |
| Website | www.ajantapharma.com |
| Revenue | ₹1,794 Cr |
|---|---|
| Net Profit | ₹388 Cr |
| Net Margin | 21.6% |
| EPS (Basic) | ₹31.07 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Ajanta Pharma Limited reported revenue of ₹1,794 Cr in Q2 FY27, up 32.5% from ₹1,354 Cr in Q2 FY26 and up 10.3% from ₹1,626 Cr in Q1 FY27. It posted a net profit of ₹388 Cr for the quarter, against a net profit of ₹260 Cr in Q2 FY26 (up 49.2%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹1,170 Cr (Q4 FY25) to ₹1,794 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹1,794 Cr | ₹388 Cr | 21.6% |
| Q1 FY27 | ₹1,626 Cr | ₹334 Cr | 20.6% |
| Q4 FY26 | ₹1,422 Cr | ₹267 Cr | 18.8% |
| Q3 FY26 | ₹1,375 Cr | ₹274 Cr | 19.9% |
| Q2 FY26 | ₹1,354 Cr | ₹260 Cr | 19.2% |
| Q1 FY26 | ₹1,303 Cr | ₹255 Cr | 19.6% |
| Q4 FY25 | ₹1,170 Cr | ₹225 Cr | 19.2% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 63.47% of Ajanta Pharma Limited's shares as of Sept 2026, against 66.25% in Sept 2025 (−2.78 percentage points). Delivery averaged 53.9% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Ajanta Pharma Limited, together with its subsidiaries, a pharmaceutical formulation company that develops, manufactures, and markets specialty pharmaceutical finished dosages. The company offers chronic and acute therapies; branded generic products; and a range of dosage forms, including tablets, capsules, injectables, inhalers, ointments, creams, and liquids. It also serves various therapeutic areas comprising cardiology, dermatology, ophthalmology, and pain management. The company operates in India, Africa, Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.
1. Pharmaceuticals-This segment offers pharmaceutical and related products. 2. Pharmaceuticals-This segment offers pharmaceuticals and related products.
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Astrazeneca Pharma India Ltd. | ₹16,078 Cr | 85.9 | 22.82% | ₹729 Cr | -34.3% |
Listed by market capitalisation. Ratios are shown for context only.
Ajanta Pharma Limited is trading at ₹3,279.00, with a market capitalisation of ₹41,474 Cr.
Ajanta Pharma Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Ajanta Pharma Limited has a P/E of 39.4 and a return on equity of 25.39%.
Ajanta Pharma Limited is listed on the NSE under the symbol AJANTPHARM and on the BSE under the scrip code 532331.
Ajanta Pharma Limited's share price is up 27.8% over one year and down 9.1% over three months. Its 52-week range is ₹2,445.80 to ₹3,796.00.
In Q2 FY27, Ajanta Pharma Limited reported revenue of ₹1,794 Cr and net profit of ₹388 Cr, with basic EPS of ₹31.07 (consolidated, parsed from the company's exchange filing).
Ajanta Pharma Limited reported revenue of ₹1,794 Cr in Q2 FY27, up 32.5% from ₹1,354 Cr in Q2 FY26 and up 10.3% from ₹1,626 Cr in Q1 FY27.
Promoters held 63.47% of Ajanta Pharma Limited's shares as of Sept 2026, against 66.25% in Sept 2025 (−2.78 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.